Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811767 | 0.85 | KMT2A (0.44) | KMT2AMEN1HTR6HTR2AALDH1A1 | |
| SCHEMBL19252150 | 0.85 | KMT2A (0.44) | KMT2AMEN1HTR6HTR2AALDH1A1 | |
| SCHEMBL28952974 | 0.85 | HTR6 (0.43) | KMT2AMEN1HTR6HTR2AALDH1A1 | |
| SCHEMBL20762057 | 0.81 | BRD4 (0.49) | HTR6BRD4SRCPTGDRPTGDR2 | |
| SCHEMBL30958211 | 0.81 | MEN1 (0.45) | KMT2AMEN1HTR6HTR2AALDH1A1 | |
| SCHEMBL17422100 | 0.80 | AGTR1 (0.41) | KMT2AMEN1HTR6HTR2AALDH1A1 | |
| SCHEMBL15558579 | 0.77 | BRD4 (0.46) | HTR6BRD4PSEN1PSEN2APH1B | |
| SCHEMBL597369 | 0.77 | HTR6 (0.46) | HTR6BRD4PSEN1PSEN2APH1B | |
| SCHEMBL15558039 | 0.77 | HTR6 (0.49) | HTR6BRD4GAASRCPTGDR | |
| SCHEMBL30644289 | 0.77 | HTR6 (0.46) | HTR6BRD4PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-2875018-B1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2018-02-14 | — | — | EP | disclosed |
| CN-107459508-A | Annelated pyrimidines as the inhibitor of P97 compounds | 克里弗生物科学公司 | 2017-12-12 | — | — | CN | disclosed |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-3208270-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-3208270-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| CN-104768946-B | Fused pyrimidines as inhibitors of the p97 complex | 克里弗生物科学公司 | 2017-05-03 | — | — | CN | disclosed |
| US-9475824-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475824-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| CN-104768946-A | Fused pyrimidines as inhibitors of the p97 complex | CLEAVE BIOSCIENCES INC | 2015-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | PSMG3, PSME1, PSMB1 | KMT2A 3080/4885MEN1 4188/4885HTR6 4171/4885 |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | PSMG3, PSME1, PSMB1 | KMT2A 3080/4885MEN1 4188/4885HTR6 4171/4885 |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | PSMG3, PSME1, PSMB1 | KMT2A 3080/4885MEN1 4188/4885HTR6 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.